Health Care · Surgical & Medical Instruments & Apparatus

SGHT Sight Sciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 153117787 filings
Russell 2000

SGHT at a glance

Sight Sciences, Inc. (SGHT, SEC CIK 1531177) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Sight Sciences, Inc. (SGHT) reported revenue of $77.4 million (down 3.1% from FY2024) and a net loss of $38.4 million. Diluted EPS was -$0.74.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Sight Sciences, Inc. (SGHT) shares worth $90.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Taylor Brenton on November 16, 2026 of 20,685 shares at $10.64 per share.
  • In the last 90 days, SGHT insiders reported 0 open-market purchases ($0) and 6 open-market sales ($873K) on Form 4, a net sale of $873K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$77.4M
−3.1% vs prior year
Insiders · 90 days
0 buys · 6 sells
Net −$873K
13F holders
25 funds
$90.7M · +1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $24.9M, up 25.2% YoY from $19.9M
  • Interventional Dry Eye strongest growth: $3.9M revenue vs $0.2M, gross margin 79.0% vs 37.8%
  • Interventional Glaucoma largest segment: $21.0M revenue, up 6.7% YoY
  • Total gross margin 85.9% vs 86.4% YoY, operating loss $6.1M vs $7.9M
  • Cash $77.4M; operating cash use $15.1M vs $27.9M, management expects liquidity beyond 12 months

Risk Factors

  • No material changes to risk factors since the Annual Report
  • Business, results, liquidity, and prospects vulnerable to identified or currently unknown risks
  • Common-stock trading price could decline, potentially causing total or partial investment loss

AI summary of the SGHT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026
  • Full-year 2026 revenue guidance raised, signaling improved expected sales performance

Item 7.01: Regulation FD Disclosure

  • Investor presentation posted November 4, 2026, intended for investor and analyst communications
  • Exhibit 99.2 contains the presentation, potentially including updated strategy, operating metrics, or financial guidance

Item EX-99.1: Item EX-99.1

  • Q3 revenue $24.9M, up 25% year over year, signaling accelerating commercial traction
  • IDE revenue $3.9M versus $0.2M, with 222 active customers and 4,581 treatment units sold

Item EX-99.2: Item EX-99.2

  • Q3 2026 revenue $24.9M, up 25% YoY, marking a third consecutive quarter of double-digit growth
  • FY2026 revenue guidance $92M-$93M, up 19%-20% YoY, signaling accelerating commercial momentum
Filed Aug 10, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Kashif Rashid appointed Chief Legal Officer and Corporate Secretary effective August 10, 2026
  • $450,000 base salary and 50% target annual cash bonus
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $23.4M, up 20% YoY; glaucoma revenue rose 8% while dry-eye revenue surged 704% to $2.7M
  • Gross margin reached 91.4%, with dry-eye margin improving to 84.7% from 38.4% YoY

Item 7.01: Regulation FD Disclosure

  • Investor presentation posted August 5, 2026 under Regulation FD
  • Exhibit 99.2 contains materials management expects to use with investors and analysts

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results announced for quarter ended June 30, 2026
  • 2026 revenue guidance raised, signaling stronger expected sales performance

Item EX-99.2: Item EX-99.2

  • FY2026 revenue guidance: $88M-$92M, implying return to double-digit growth and approximately 13% CAGR from FY2021
  • Q2 2026 revenue growth: 20% year over year, supporting the company’s projected growth recovery

AI summaries of SGHT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SGHT

Don't miss the next SGHT filing

  • Alerts as it files. A push when SGHT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SGHT, by share count.
  • Ask anything. An AI agent that reads every SGHT filing and answers with sources.

SGHT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Taylor BrentonSellNov 16, 2026$10.64
Bauerlein AlisonSellOct 2, 2026$8.85
Taylor BrentonSellOct 2, 2026$8.85
Rodberg JamesSellOct 2, 2026$8.85
Badawi DavidSellOct 1, 2026$9.05
Badawi PaulSellOct 1, 2026$9.05
Rashid KashifAAug 10, 2026-
HAYDEN JEREMY B.SellJul 6, 2026$5.51

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$79.9M$77.4M
Gross Profit-$68.3M$66.7M
Operating Income--$50.5M-$37.1M
Net Income--$51.5M-$38.4M
Gross Margin-85.5%86.2%
Op. Margin--63.3%-48.0%
Net Margin--64.5%-49.7%
Balance Sheet
Total Assets$166.7M$142.8M$115.3M
Equity$120.2M$87.5M$63.9M
ROE--58.8%-60.1%
Per Share
EPS-$-1.03$-0.74
Cash Flow
Operating CF--$22.4M-$29.7M
CapEx-$385K$224K

Source: XBRL data in Sight Sciences, Inc. (SGHT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SGHT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SGHT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$90.7M
Q2 202624$45.7M
Q1 202625$30.1M
Q4 202523$66.7M
Q3 202520$25.6M
Q2 202520$30.5M
Q1 202518$13.9M
Q4 202413$15.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 168 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SGHT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
4Aug 18, 2026--
8-KAug 10, 2026Analysis-
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jun 11, 2026--
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
8-KJun 5, 2026Analysis

Related Health Care companies

All Health Care →

SGHT SEC filings: frequently asked questions

Are SGHT insiders buying or selling?

In the last 90 days, Sight Sciences, Inc. (SGHT) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $872,783 by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold SGHT stock?

As of September 30, 2026, the largest Sight Sciences, Inc. (SGHT) holders among the 13F filers tracked by SignalX were BlackRock ($31.5 million), Vanguard Capital Management LLC ($15.3 million), State Street Corp ($7.9 million), Millennium Management ($6.6 million), Dimensional Fund Advisors ($3.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SGHT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Sight Sciences, Inc. (SGHT) reported revenue of $77.4 million (down 3.1% from FY2024) and a net loss of $38.4 million. Diluted EPS was -$0.74. The figures come from the XBRL data in the 10-K.

What did SGHT report in its latest 8-K?

Sight Sciences, Inc. (SGHT) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 results announced for quarter ended September 30, 2026.

What are the latest SGHT SEC filings?

Sight Sciences, Inc. (SGHT) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.

What is SGHT's SEC CIK number?

Sight Sciences, Inc. (SGHT)'s SEC Central Index Key (CIK) is 1531177. EDGAR lists every SGHT filing under that number.

Ask anything about SGHT

The research agent reads SGHT's filings, financials, insider trades and 13F holders, then answers with sources.